Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with poor prognosis and limited therapeutic options, and it accounts for 15%-20% of female invasive breast cancers.
Investigators at Ileadbms Co. Ltd. have discovered a new cyclin-dependent kinase 12 (CDK12) and CDK13 inhibitor, IL6-110, which is being developed for the treatment of cancer.
Monopar Therapeutics Inc. has received human research ethics committee (HREC) clearance in Australia to commence a first-in-human phase I dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr in patients with advanced cancers.
Triple-negative breast cancer (TNBC) accounts for about 15% of invasive breast cancers, and due to the lack of well-established targets, TNBC has the worst prognosis among all breast cancer types.
Researchers from The Cleveland Clinic Foundation presented a novel targeted therapeutic peptide for the treatment of triple-negative breast cancer (TNBC).
Accent Therapeutics Inc. has completed a $75 million series C financing to support progression of its lead programs through early clinical development.
Presage Biosciences Inc. has announced that the FDA has issued a study may proceed notification for testing a pre-GMP drug candidate with the company’s Comparative In Vivo Oncology (CIVO) platform. Owned by Pure Biologics, the drug candidate, PBA-0405, is a ROR1-targeting compound that has been engineered to induce tumor cell killing by cytotoxic immune cells.
